Rapid drug desensitization to taxanes : a descriptive study from Turkey
AIM: To present the characteristics of drug hypersensitivity reactions (DHRs) among taxane recipients with non-small cell lung carcinoma (NSCLC), and to describe the results of rapid drug desensitization (RDD).
METHODS: A retrospective cross-sectional study included 45 patients who were treated with taxane for NSCLC and were found to be hypersensitive to taxane. All patients were administered the standard 3-bag, 12-step RDD protocol following the development of DHR. RDD success was evaluated separately for each cycle, and successful RDD was defined as the completion of the cycle with application of 12 steps of the desensitization protocol and the absence of early and/or late reactions afterwards.
RESULTS: Among 45 patients hypersensitive to taxane 43 (95.6%) successfully received taxane cycles with desensitization. Failed RDD occurred in only 2 (4.4%) patients. The total number of desensitization cycles was 183, of which 181 (98.9%) were successful. The mean age of patients with successful desensitization was 59.42 ± 10.48 years and 37 (86.0%) of them were male.
CONCLUSION: RDD is a reliable procedure that enables effective administration and completion of first-line taxane treatments in taxane-sensitive patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners - (2023) vom: 07. Nov., Seite 10781552231213318 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yeşilkaya, Selma [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Breakthrough hypersensitivity reaction |
|---|
| Anmerkungen: |
Date Revised 08.11.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1177/10781552231213318 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364281480 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364281480 | ||
| 003 | DE-627 | ||
| 005 | 20231226095117.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/10781552231213318 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1214.xml |
| 035 | |a (DE-627)NLM364281480 | ||
| 035 | |a (NLM)37936390 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yeşilkaya, Selma |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Rapid drug desensitization to taxanes |b a descriptive study from Turkey |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 08.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a AIM: To present the characteristics of drug hypersensitivity reactions (DHRs) among taxane recipients with non-small cell lung carcinoma (NSCLC), and to describe the results of rapid drug desensitization (RDD) | ||
| 520 | |a METHODS: A retrospective cross-sectional study included 45 patients who were treated with taxane for NSCLC and were found to be hypersensitive to taxane. All patients were administered the standard 3-bag, 12-step RDD protocol following the development of DHR. RDD success was evaluated separately for each cycle, and successful RDD was defined as the completion of the cycle with application of 12 steps of the desensitization protocol and the absence of early and/or late reactions afterwards | ||
| 520 | |a RESULTS: Among 45 patients hypersensitive to taxane 43 (95.6%) successfully received taxane cycles with desensitization. Failed RDD occurred in only 2 (4.4%) patients. The total number of desensitization cycles was 183, of which 181 (98.9%) were successful. The mean age of patients with successful desensitization was 59.42 ± 10.48 years and 37 (86.0%) of them were male | ||
| 520 | |a CONCLUSION: RDD is a reliable procedure that enables effective administration and completion of first-line taxane treatments in taxane-sensitive patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Taxanes | |
| 650 | 4 | |a breakthrough hypersensitivity reaction | |
| 650 | 4 | |a drug hypersensitivity reactions | |
| 650 | 4 | |a non-small cell lung cancer | |
| 650 | 4 | |a rapid drug desensitization | |
| 700 | 1 | |a Aksu, Kurtuluş |e verfasserin |4 aut | |
| 700 | 1 | |a Vural Solak, Gürgün Tuğçe |e verfasserin |4 aut | |
| 700 | 1 | |a Demir, Şenay |e verfasserin |4 aut | |
| 700 | 1 | |a Topel, Musa |e verfasserin |4 aut | |
| 700 | 1 | |a Erçelebi, Dilek Çuhadar |e verfasserin |4 aut | |
| 700 | 1 | |a Koca Kalkan, İlkay |e verfasserin |4 aut | |
| 700 | 1 | |a Ateş, Hale |e verfasserin |4 aut | |
| 700 | 1 | |a Köycü Buhari, Gözde |e verfasserin |4 aut | |
| 700 | 1 | |a Nazik Bahçecioğlu, Sakine |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners |d 1997 |g (2023) vom: 07. Nov., Seite 10781552231213318 |w (DE-627)NLM094530254 |x 1477-092X |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:07 |g month:11 |g pages:10781552231213318 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/10781552231213318 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 07 |c 11 |h 10781552231213318 | ||